Those
findings are among results of six studies of investigational chimeric antigen receptor (CAR) T cells for both adult and
pediatric leukemias, adult lymphomas, and ovarian cancer which will be presented during the 2016 American Society of Clinical
Oncology Annual Meeting.
These initial
findings have paved the way to expand the program into a more comprehensive
pediatric precision
oncology program that researchers expect to launch in 2016, which will include offering sequencing to
pediatric cancer patients diagnosed at other hospitals.